drugset / Trial / NCT03984045

SPG Block for Acute Pediatric Migraine

NCT03984045

Phase 3 Unknown 72 enrolled Newark Beth Israel Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized double blind trial comparing an intranasal sphenopalatine block with 2% lidocaine to intravenous (0.15 mg/kg, max 10mg) prochlorperazine in patients greater than 10 years of age presenting to a pediatric emergency department with an acute frontal migraine headache.

Timeline

Start
2019-06-06
Primary completion
2022-06-30
Completion
2022-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 2 % Intranasal
Comparator Prochlorperazine Small molecule 0.15 mg/kg Intravenous